Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blue Sky MD vs Rebody Health

Blue Sky MD
Graded #157

Level

vs
Rebody Health
Graded #159

Level

The verdict

Too close to call — both grade 67.7/100 (C).

Blue Sky MD and Rebody Health land on the same WeighScore, so neither clears the other on our six graded dimensions. Blue Sky MD sits one line higher on the board (#157 vs #159) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlue Sky MD +19
65
46
Dose & formulationRebody Health +24
64
88
Clinical oversightBlue Sky MD +6
87
81
Labs & monitoringBlue Sky MD +9
62
53
FulfillmentRebody Health +21
63
84
Contract termsEven
55
55
Blue Sky MD · left barRebody Health · right bar

The numbers

MetricBlue Sky MDRebody Health
WeighScore67.7/10067.7/100
GradeCC
Scorecard rank#157#159
Semaglutide$160/mo (starting dose, compounded)$200/mo (starting dose, compounded)
Tirzepatide$240/mo (starting dose, compounded)$250/mo (starting dose, compounded)
Coverage1 state47 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Blue Sky MD

Graded #157 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina
Rebody Health

Graded #159 · C

Strengths

  • Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
  • Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
  • Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
  • Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
  • Names its operating company (Compound Technologies Inc.) and references LegitScript approval

Where it loses points

  • Individual compounding pharmacies are not named on the marketing site
  • Not available in Massachusetts, Rhode Island, or Vermont
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard